Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX<Superscript>®</Superscript>) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective

For adult patients with NDO who are not adequately managed with ACHDs, onabotulinumtoxinA + BSC appears to be a cost-effective use of resources in the UK NHS. </AbstractSection> Copyright The Author(s) 2015

MoreLess

Year of publication:	2015
Authors:	Hamid, Rizwan ; Loveman, Clara ; Millen, Jim ; Globe, Denise ; Corbell, Catherine ; Colayco, Danielle ; Stanisic, Sanja ; Gultyaev, Dmitry
Published in:	PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 33.2015, 4, p. 381-393
Publisher:	Springer

Online Resource

Check full text access |

More access options

Check Google Scholar

In libraries world-wide (WorldCat)

In German libraries (KVK)

subito order

I need help

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011241569